Cell and gene therapies have demonstrated transformative clinical impact and are now entering a more advanced phase of commercialisation. However, scaling these therapies in a consistent, cost-effective, and globally accessible way remains a significant challenge. Despite continued innovation, progress is constrained by fragmented supply chains, complex manufacturing models, and ongoing questions around the sustainability of R&D investment.
Key discussion points:
How companies are adapting R&D and process development to support scalable, reproducible manufacturing
Whether current CGT supply chain models can support scale, or if a fundamental redesign is needed
What realistic pathways exist to reduce cost and complexity while maintaining quality
How investor expectations are evolving as CGT moves beyond early-stage innovation
The role of partnerships across biotech, CDMOs, and providers in enabling scale and access
